Compare NUS & LENZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NUS | LENZ |
|---|---|---|
| Founded | 1984 | 2019 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Other Pharmaceuticals | Medicinal Chemicals and Botanical Products |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 343.1M | 278.4M |
| IPO Year | 1996 | 2021 |
| Metric | NUS | LENZ |
|---|---|---|
| Price | $5.86 | $7.76 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $44.00 |
| AVG Volume (30 Days) | 574.4K | ★ 852.3K |
| Earning Date | 05-07-2026 | 05-06-2026 |
| Dividend Yield | ★ 3.36% | N/A |
| EPS Growth | ★ 207.80 | N/A |
| EPS | ★ 0.04 | N/A |
| Revenue | ★ $3,176,718,000.00 | $19,088,000.00 |
| Revenue This Year | N/A | $50.42 |
| Revenue Next Year | $7.14 | $197.16 |
| P/E Ratio | $148.38 | ★ N/A |
| Revenue Growth | ★ 48.98 | N/A |
| 52 Week Low | $5.62 | $6.61 |
| 52 Week High | $14.62 | $50.19 |
| Indicator | NUS | LENZ |
|---|---|---|
| Relative Strength Index (RSI) | 28.01 | 42.54 |
| Support Level | N/A | N/A |
| Resistance Level | $11.06 | $10.42 |
| Average True Range (ATR) | 0.29 | 0.64 |
| MACD | -0.06 | -0.03 |
| Stochastic Oscillator | 13.03 | 30.35 |
Nu Skin Enterprises Inc develops and distributes a comprehensive line of beauty and wellness solutions in various countries. The company operates in two primary product categories: beauty and wellness products. Additionally, the company also operates through its subsidiary, Rhyz. It reports revenue from nine segments, consisting of its seven geographic Nu Skin segments: Americas, Southeast Asia/Pacific, Mainland China, Japan, Europe & Africa, South Korea, and Hong Kong/Taiwan and two Rhyz segments: manufacturing, which includes manufacturing and packaging subsidiaries it has acquired; and Rhyz Other, which includes other investments by its Rhyz strategic investment arm. The majority of the company's revenue is generated from the Wellness product category from the Americas segment.
LENZ Therapeutics Inc is a late-stage biopharmaceutical company focused on developing and commercializing therapies to improve vision and developing ophthalmic pharmaceutical products. Its products VIZZ (aceclidine ophthalmic solution) 1.44% is a once-daily eye drop developed to restore clear near vision for up to 10 hours. VIZZ is powered by aceclidine, highlighted by its differentiated mechanism of action as a predominantly pupil-selective miotic that interacts with the iris, with minimal ciliary muscle stimulation.